Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
2.850
-0.050 (-1.72%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Akoya Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 93.22 | 96.63 | 74.86 | 54.92 | 42.44 | 42.24 |
| Revenue Growth (YoY) | 9.66% | 29.09% | 36.31% | 29.39% | 0.49% | - |
| Cost of Revenue | 39.56 | 40.33 | 31.47 | 20.7 | 16.54 | 17.57 |
| Gross Profit | 53.66 | 56.31 | 43.39 | 34.22 | 25.91 | 24.66 |
| Selling, General & Admin | 74.31 | 82.38 | 79.65 | 51.02 | 23.98 | 26.35 |
| Research & Development | 19.43 | 21.89 | 23.21 | 15.7 | 9.6 | 8.76 |
| Operating Expenses | 101.81 | 112.34 | 109.6 | 71.44 | 37.4 | 38.17 |
| Operating Income | -48.15 | -56.03 | -66.21 | -37.23 | -11.49 | -13.5 |
| Interest Expense | -9.75 | -8.76 | -4.55 | -3.12 | -2.72 | -1.88 |
| Interest & Investment Income | 3.59 | 3.49 | 0.78 | 0.09 | - | - |
| Other Non Operating Income (Expenses) | -1.46 | -0.35 | -0.86 | -3.23 | -0.26 | -0.37 |
| EBT Excluding Unusual Items | -55.76 | -61.65 | -70.84 | -43.48 | -14.47 | -15.76 |
| Gain (Loss) on Sale of Investments | 1.03 | 0.01 | 0.22 | - | - | - |
| Other Unusual Items | -1.15 | -1.64 | 0.1 | 0.4 | -2.19 | 1.2 |
| Pretax Income | -60.25 | -63.28 | -70.52 | -43.08 | -16.66 | -14.56 |
| Income Tax Expense | 0.1 | 0.04 | 0.12 | -0.14 | 0.04 | 0.19 |
| Net Income | -60.35 | -63.32 | -70.64 | -42.94 | -16.71 | -14.75 |
| Preferred Dividends & Other Adjustments | - | - | - | 1.44 | 5.06 | 3.56 |
| Net Income to Common | -60.35 | -63.32 | -70.64 | -44.37 | -21.76 | -18.31 |
| Shares Outstanding (Basic) | 49 | 44 | 38 | 27 | 2 | 2 |
| Shares Outstanding (Diluted) | 49 | 44 | 38 | 27 | 2 | 2 |
| Shares Change (YoY) | 27.43% | 17.72% | 40.34% | 1034.62% | 4.15% | - |
| EPS (Basic) | -1.22 | -1.43 | -1.87 | -1.65 | -9.18 | -8.04 |
| EPS (Diluted) | -1.22 | -1.43 | -1.87 | -1.65 | -9.18 | -8.04 |
| Free Cash Flow | -53.61 | -54.55 | -60.86 | -41.16 | -10.14 | -16.65 |
| Free Cash Flow Per Share | -1.09 | -1.23 | -1.61 | -1.53 | -4.28 | -7.31 |
| Gross Margin | 57.57% | 58.27% | 57.96% | 62.31% | 61.04% | 58.39% |
| Operating Margin | -51.65% | -57.98% | -88.44% | -67.78% | -27.08% | -31.97% |
| Profit Margin | -64.74% | -65.53% | -94.37% | -80.79% | -51.27% | -43.34% |
| Free Cash Flow Margin | -57.51% | -56.45% | -81.29% | -74.95% | -23.89% | -39.41% |
| EBITDA | -39.49 | -47.14 | -59.06 | -32.43 | -7.68 | -10.45 |
| EBITDA Margin | -42.36% | -48.78% | -78.89% | -59.06% | -18.09% | -24.74% |
| D&A For EBITDA | 8.66 | 8.89 | 7.15 | 4.79 | 3.82 | 3.06 |
| EBIT | -48.15 | -56.03 | -66.21 | -37.23 | -11.49 | -13.5 |
| EBIT Margin | -51.65% | -57.98% | -88.44% | -67.78% | -27.08% | -31.97% |
| Revenue as Reported | 93.22 | 96.63 | 74.86 | 54.92 | 42.44 | 42.24 |
| Advertising Expenses | - | 2.33 | 4.64 | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.